The chance of small interfering RNAs as eligible candidates for a personalized treatment of prostate cancer

Current Pharmaceutical Biotechnology

Volumn 14, Issue 13, 2014, Pages 1145-1154

  Pietschke, Katharina ^a   Walker, Tobias ^a   Krajewski, Stefanie ^a   Kurz, Julia ^a   Aufderklamm, Stefan ^a   Schwentner, Christian ^a   Schlensak, Christian ^a   Stenzl, Arnulf ^a   Wendel, Hans P ^a   Nolte, Andrea ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

E2F1; Hypoxia induced factors; RNA interference; Serum response factor; STAT3; Survivin

Indexed keywords

COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SERUM RESPONSE FACTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR E2F1; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; MALE; PERSONALIZED MEDICINE; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84903690616     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140507155138     Document Type: Article

References (40)

1. Li, J.; Djenaba, J. A.; Soman, A.; Rim, S. H.; Master, V. A., Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer, 2012, 2012, 691380.
2. Yablon, C.M.; Banner, M.P.; Ramchandani, P.; Rovner, E.S. Complications of prostate cancer treatment: Spectrum of imaging findings. Radiographics, 2004, 24(Suppl 1), S181-94.
3. Pienta, K.J.; Esper, P.S. Risk factors for prostate cancer. Ann. Intern. Med., 1993, 118(10), 793-803.
4. Krupski, T. L.; Stukenborg, G. J.; Moon, K.; Theodorescu, D. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int., 2010, 106(10), 1477-83.
5. Perry, M.J.; Roodhouse, A.J.; Gidlow, A.B.; Spicer, T.G.; Ellis, B.W. Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int., 2002, 90(3), 216-23.
6. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 2001, 409(6818), 363-6.
7. Wang, X.; Chen, Y.; Ren, J.; Qu, X., Small interfering RNA for effective cancer therapies. Mini Rev. Medicin.Chem., 2011, 11(2), 114-124.
8. Makowiecki, C.; Nolte, A.; Sutaj, B.; Keller, T.; Avci-Adali, M.; Stoll, H.; Schlensak, C.; Wendel, H. P.; Walker, T. New basic approach to treat non-small cell lung cancer based on RNAinterference. Thoracic Cancer, 2014, 5(2), 112-120;
9. Mircea G.S.; Andrea, N.; Julia, K.; Martin, M.; Jindrich, C.; Volker, S.; Christian, S.; Hans, P.W.; Walker, T. Experimental evaluation of gene silencing as new therapeutic option in the treatment of gemcitabine-chemoresistant non-small-cell lung cancer. J. Thorac. Oncol., 2013, Submitted.
10. Walker, T.; Wendel, H.P.; Raabe, C.; Wiechnik, P.; Spranger, L.; Heidenreich, O.; Scheule, A.M.; Nordheim, A.; Ziemer, G. Graft protection in bypass surgery: siRNA-mediated silencing of adhesion molecules. Oligonucleotides, 2009, 19(1), 15-21;
11. Walker, T.; Muller, I.; Raabe, C.; Nohe, B.; Zanke, C.; Ziemer, G.; Wendel, H.P. Effective silencing of adhesion molecules on venous endothelial cells for protection of venous bypass grafts. Eur. J. Cardiothorac. Surg., 2011, 40(5), 1241-1247.
12. Gao, L.F.; Xu, D.Q.; Shao, Y.T.; Zhao, D.; Zhao, X.J. [Knockdown of STAT3 expression using siRNA inhibits the growth of prostate cancer cell lines]. Zhonghua nan ke xue = Nat. J. Androl., 2005, 11(1), 29-33, 37.
13. Ren, Z.; Kang, W.; Wang, L.; Sun, B.; Ma, J.; Zheng, C.; Sun, J.; Tian, Z.; Yang, X.; Xiao, W. E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-kappaB modulation. Mol. Cancer, 2014, 13(1), 84.
14. Liu, X.; Gao, R.; Dong, Y.; Gao, L.; Zhao, Y.; Zhao, L.; Zhao, X.; Zhang, H. Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition. BMC Cancer, 2010, 10, 418;
15. Shen, J.; Liu, J.; Long, Y.; Miao, Y.; Su, M.; Zhang, Q.; Han, H.; Hao, X. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim. Et Biophysic. Sinic. 2009, 41(3), 223-230.
16. Liu, X. Q.; Xiong, M. H.; Shu, X. T.; Tang, R. Z.; Wang, J. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol. Pharm., 2012, 9(10), 2863-2874.
17. Werth, D.; Grassi, G.; Konjer, N.; Dapas, B.; Farra, R.; Giansante, C.; Kandolf, R.; Guarnieri, G.; Nordheim, A.; Heidenreich, O. Proliferation of human primary vascular smooth muscle cells depends on serum response factor. Eur. J. Cell Biol., 2010, 89(2-3), 216-224.
18. Jing, N.; Tweardy, D.J. Targeting Stat3 in cancer therapy. Anti-Cancer Drugs, 2005, 16(6), 601-7.
19. Semenza, G.L. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends in molecular medicine 2001, 7(8), 345-350.
20. Putzer, B.M. E2F1 death pathways as targets for cancer therapy. J. Cellul. Molecul. Med., 2007, 11(2), 239-51.
21. Altieri, D.C. Survivin, cancer networks and pathway-directed drug discovery. Nature reviews. Cancer, 2008, 8(1), 61-70.
22. Walker, T.; Nolte, A.; Steger, V.; Makowiecki, C.; Mustafi, M.; Friedel, G.; Schlensak, C.; Wendel, H.P. Small interfering RNAmediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection. Eur. J. Cardiothorac. Surg., 2013, 43(3), 628-33; discussion 633-4.
23. Nolte, A.; Aufderklamm, S.; Scheu, K.; Walker, T.; Konig, O.; Bottcher, M.; Niederlaender, J.; Schwentner, C.; Schlensak, C.; Stenzl, A.; Wendel, H.P. Small interfering RNA transfection against serum response factor mediates growth inhibition of benign prostatic hyperplasia fibroblasts. Nucleic Acid Therapeut., 2013, 23(1), 62-70.
24. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W.S.; Khvorova, A., Rational siRNA design for RNA interference. Nat. Biotechnol., 2004, 22(3), 326-30.
25. Stoleriu, M.G.; Steger, V.; Mustafi, M.; Michaelis, M.; Cinatl, J.; Schneider, W.; Nolte, A.; Kurz, J.; Wendel, H. P.; Schlensak, C.; Walker, T., A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3. Eur. J. Cardiothorac. Surg., 2014.
26. Nolte, A.; Raabe, C.; Walker, T.; Simon, P.; Ziemer, G.; Wendel, H.P. Optimized basic conditions are essential for successful siRNA transfection into primary endothelial cells. Oligonucleotides, 2009, 19 (2), 141-150.
27. Burley, S. K.; Kamada, K. Transcription factor complexes. Current opinion in structural biology 2002, 12 (2), 225-30;
28. Brandt, D. T.; Xu, J.; Steinbeisser, H.; Grosse, R. Regulation of myocardin-related transcriptional coactivators through cofactor interactions in differentiation and cancer. Cell Cycle, 2009, 8 (16), 2523-2527.
29. Alvarez, J.V.; Greulich, H.; Sellers, W.R.; Meyerson, M.; Frank, D.A. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res., 2006, 66(6), 3162-3168.
30. Klampfer, L., Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets, 2006, 6(2), 107-121.
31. Fagard, R.; Metelev, V.; Souissi, I.; Baran-Marszak, F., STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT, 2013, 2(1), e22882.
32. Percy, M. J.; Furlow, P. W.; Lucas, G. S.; Li, X.; Lappin, T. R.; McMullin, M. F.; Lee, F. S., A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med., 2008, 358(2), 162-168.
33. Semenza, G. L., Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3(10), 721-732.
34. Wu, C. L.; Zukerberg, L. R.; Ngwu, C.; Harlow, E.; Lees, J. A. In vivo association of E2F and DP family proteins. Mol. Cell Biol., 1995, 15(5), 2536-46;
35. Emmrich, S.; Putzer, B. M., Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle, 2010, 9(13), 2555-2567.
36. Blattner, C.; Sparks, A.; Lane, D., Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell Biol., 1999, 19(5), 3704-3713.
37. Davis, J. N.; Wojno, K. J.; Daignault, S.; Hofer, M. D.; Kuefer, R.; Rubin, M. A.; Day, M. L., Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res., 2006, 66(24), 11897-11906.
38. Adida, C.; Crotty, P. L.; McGrath, J.; Berrebi, D.; Diebold, J.; Altieri, D. C., Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol., 1998, 152(1), 43-49.
39. Escuin, D.; Rosell, R., The anti-apoptosis survivin gene and its role in human cancer: an overview. Clin. Lung Cancer 1999, 1(2), 138-143.
40. Khan, S.; Jutzy, J. M.; Valenzuela, M. M.; Turay, D.; Aspe, J. R.; Ashok, A.; Mirshahidi, S.; Mercola, D.; Lilly, M. B.; Wall, N. R. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One, 2012, 7(10), e46737.